Bourgeon Capital Management LLC lessened its holdings in Becton Dickinson and Co (NYSE:BDX) by 27.3% during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 15,352 shares of the medical instruments supplier’s stock after selling 5,779 shares during the period. Becton Dickinson and makes up approximately 2.1% of Bourgeon Capital Management LLC’s portfolio, making the stock its 20th biggest holding. Bourgeon Capital Management LLC’s holdings in Becton Dickinson and were worth $3,883,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also made changes to their positions in BDX. TRUE Private Wealth Advisors purchased a new position in Becton Dickinson and in the second quarter valued at approximately $25,000. Allworth Financial LP lifted its stake in Becton Dickinson and by 386.4% in the third quarter. Allworth Financial LP now owns 107 shares of the medical instruments supplier’s stock valued at $27,000 after purchasing an additional 85 shares during the last quarter. Northwest Investment Counselors LLC purchased a new position in Becton Dickinson and in the third quarter valued at approximately $27,000. Hexavest Inc. purchased a new position in Becton Dickinson and in the second quarter valued at approximately $28,000. Finally, Lipe & Dalton purchased a new position in Becton Dickinson and in the second quarter valued at approximately $28,000. Hedge funds and other institutional investors own 84.29% of the company’s stock.
BDX stock traded up $0.22 during midday trading on Friday, reaching $244.79. 1,491,912 shares of the company’s stock traded hands, compared to its average volume of 1,173,922. The company has a 50-day moving average price of $251.93 and a two-hundred day moving average price of $246.89. The company has a debt-to-equity ratio of 0.85, a quick ratio of 0.67 and a current ratio of 1.19. Becton Dickinson and Co has a 52 week low of $208.62 and a 52 week high of $264.74. The firm has a market capitalization of $66.59 billion, a PE ratio of 20.96, a price-to-earnings-growth ratio of 1.62 and a beta of 1.09.
Becton Dickinson and (NYSE:BDX) last issued its earnings results on Tuesday, November 5th. The medical instruments supplier reported $3.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.30 by $0.01. Becton Dickinson and had a net margin of 6.84% and a return on equity of 15.51%. The business had revenue of $4.58 billion for the quarter, compared to analysts’ expectations of $4.57 billion. During the same quarter in the previous year, the firm posted $2.93 EPS. The business’s revenue for the quarter was up 4.1% compared to the same quarter last year. As a group, analysts predict that Becton Dickinson and Co will post 12.58 EPS for the current fiscal year.
In other Becton Dickinson and news, SVP Charles R. Bodner sold 1,514 shares of the business’s stock in a transaction on Friday, September 6th. The shares were sold at an average price of $260.08, for a total transaction of $393,761.12. Following the sale, the senior vice president now owns 5,180 shares of the company’s stock, valued at approximately $1,347,214.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Alexandre Conroy sold 9,829 shares of the business’s stock in a transaction on Thursday, August 29th. The shares were sold at an average price of $255.06, for a total transaction of $2,506,984.74. Following the sale, the executive vice president now directly owns 16,535 shares in the company, valued at approximately $4,217,417.10. The disclosure for this sale can be found here. Insiders have sold a total of 32,174 shares of company stock worth $8,354,013 in the last three months. Insiders own 0.12% of the company’s stock.
Several equities analysts recently commented on the company. Piper Jaffray Companies dropped their price objective on Becton Dickinson and from $267.00 to $266.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 6th. Morgan Stanley upped their price objective on Becton Dickinson and from $250.00 to $261.00 and gave the company an “equal weight” rating in a research note on Tuesday, July 16th. ValuEngine downgraded Becton Dickinson and from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. Finally, Wells Fargo & Co dropped their price objective on Becton Dickinson and from $290.00 to $285.00 and set an “outperform” rating on the stock in a research note on Wednesday. Five investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $266.09.
About Becton Dickinson and
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.